Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. With a focus on stopping oxidative tissue damage, the company offers powerful, targeted therapies for various eye diseases and serious chronic conditions. Nacuity has several highly differentiated clinical programs, including treatments for retinitis pigmentosa, cataract, and cystinosis.

The company is currently working on obtaining proof-of-concept data for all three programs. Nacuity aims to expand the science and clinical potential for prescription products that address diseases and conditions involving oxidative stress. Drawing on the extensive research of Dr.

Peter Campochiaro of the Wilmer Eye Institute, their core science is centered on the retina's oxidative stress. Headquartered in Fort Worth, TX, Nacuity was founded by veterans of Alcon Laboratories and is backed by key organizations like Foundation Fighting Blindness and RD Fund